Please Wait
Applying Filters...
menu
    • menu
    Suanfarma, at the Core of a Better Life.

    Virtual Booth

    Contact Supplier

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    Rochem, your partner in developing, sourcing, and supplying pharmaceutical & animal health ingredients of Chinese origin.

    Virtual Booth

    Contact Supplier

    Transo-Pharm GmbH works globally to supply Active Pharmaceutical Ingredients adhering to the highest quality & GMP standards.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2025-01-20

    Virtual Booth

    Contact Supplier

    Menu

    Sabizabulin

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Veru Reaches Agreement with FDA on New Phase 3 Clinical Trial for Sabizabulin
    Veru Reaches Agreement with FDA on New Phase 3 Clinical Trial for Sabizabulin

    26 Sep 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2023/09/26/2749503/11676/en/Veru-Reaches-Agreement-with-FDA-on-New-Phase-3-Clinical-Trial-for-Sabizabulin-for-Broader-Indication-Hospitalized-Adult-Patients-with-Any-Type-of-Viral-Acute-Respiratory-Distress-S.html

    GLOBENEWSWIRE
    26 Sep 2023
    Share Share
    Veru Reaches Agreement with FDA on Confirmatory pH 3 Trial for Sabizabulin
    Veru Reaches Agreement with FDA on Confirmatory pH 3 Trial for Sabizabulin

    04 May 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2023/05/04/2661514/11676/en/Veru-Reaches-Agreement-with-FDA-on-Confirmatory-Phase-3-Clinical-Trial-for-Sabizabulin-Treatment-of-Hospitalized-COVID-19-Adult-Patients-at-High-Risk-for-ARDS.html

    GLOBENEWSWIRE
    04 May 2023
    Share Share
    Veru Announces Study Results that Demonstrate Sabizabulin Inhibits Poxviruses
    Veru Announces Study Results that Demonstrate Sabizabulin Inhibits Poxviruses

    11 Apr 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2023/04/11/2644393/11676/en/Veru-Announces-Preclinical-Study-Results-that-Demonstrate-Sabizabulin-Inhibits-Poxviruses.html

    GLOBENEWSWIRE
    11 Apr 2023
    Share Share
    Veru Announces Preclinical Results from Expanded Sabizabulin Program
    Veru Announces Preclinical Results from Expanded Sabizabulin Program

    04 Apr 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2023/04/04/2640676/11676/en/Veru-Announces-Preclinical-Results-from-Expanded-Sabizabulin-Program-into-Influenza-Induced-Severe-Acute-Respiratory-Distress-Syndrome-and-Provides-Update-on-COVID-19-Program.html

    GLOBENEWSWIRE
    04 Apr 2023
    Share Share
    Veru to proceed with late-stage study of COVID pill despite FDA snub
    Veru to proceed with late-stage study of COVID pill despite FDA snub

    14 Mar 2023

    // REUTERS

    https://www.reuters.com/business/healthcare-pharmaceuticals/veru-proceed-with-late-stage-study-covid-pill-despite-fda-snub-2023-03-14/

    REUTERS
    14 Mar 2023
    Share Share
    FDA rejects Covid-19 drug over uncertainties around small trial
    FDA rejects Covid-19 drug over uncertainties around small trial

    04 Mar 2023

    // ENDPTS

    https://endpts.com/fda-rejects-covid-19-drug-over-uncertainties-around-small-trial/

    ENDPTS
    04 Mar 2023
    Share Share